Literature DB >> 17285219

[Congenital urogenital malformations associated with nephroblastomas. Long-term results of a study in Erlangen].

V Zugor1, D Krot, G E Schott.   

Abstract

BACKGROUND: Wilms' tumors are highly malignant tumors of the kidneys and are among the most frequent solid tumors of childhood, which are diagnosed for the most part before the 5th year. Various congenital anomalies are associated with a genetic predisposition and thus an increased risk of developing a Wilms' tumor. PATIENTS AND METHODS: As part of a retrospective analysis, the records from 1965 to 2003 of 66 patients with histologically confirmed Wilms' tumor were reviewed. The aim of this study was to determine the incidence and type of different urogenital malformations as well as the genetic mutations and overall survival in this patient group.
RESULTS: The patient cohort comprised 66 patients with histologically confirmed Wilms' tumor: 35 male patients (53%) and 31 female patients (47%). The overall survival after 10 years was 89.4%. All patients underwent radical nephrectomy: transperitoneal approach in 63 and lumbar approach in 3 patients. Eleven (16.7%) patients had diverse urogenital anomalies. A cytogenetic investigation was performed in 38 patients that revealed no pathological findings. The results of molecular genetic testing of tumor specimens were available for seven patients: a genetic mutation was detected in one case (heterozygous mutation R394 in exon 9 of the WT1 gene) which had already been described in the literature in conjunction with Denys-Drash syndrome. Hemihypertrophy with Beckwith-Wiedemann syndrome was present in two (3%) patients.
CONCLUSION: In patients with urogenital malformations and Wilms' tumor, it would be important to carry out further molecular genetic testing to identify possible WT1 gene mutations. Close interdisciplinary cooperation between urologists, specialists in human genetics, and pediatricians is imperative.

Entities:  

Mesh:

Year:  2007        PMID: 17285219     DOI: 10.1007/s00120-007-1294-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  15 in total

Review 1.  Wilms' tumor--model of a curable pediatric malignant solid tumor.

Authors:  D M Green; N Jaffe
Journal:  Cancer Treat Rev       Date:  1978-09       Impact factor: 12.111

2.  Congenital anomalies in children with Wilms' tumor: a new survey.

Authors:  T W Pendergrass
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

3.  [Denys-Drash syndrome. Experience gathered in Erlangen illustrated by two case reports].

Authors:  V Zugor; M Zenker; J Dötsch; K M Schrott; G E Schott
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

4.  WT-1 is required for early kidney development.

Authors:  J A Kreidberg; H Sariola; J M Loring; M Maeda; J Pelletier; D Housman; R Jaenisch
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

5.  [Aniridia and Wilms' tumor (Miller's syndrome)].

Authors:  R Rochels
Journal:  Klin Padiatr       Date:  1981-05       Impact factor: 1.349

6.  Wilms' tumor associated with Moyamoya disease: a case report.

Authors:  Y Watanabe; T Todani; T Fujii; A Toki; S Uemura; Y Koike
Journal:  Z Kinderchir       Date:  1985-04

7.  Chromosome analysis of 31 Wilms' tumors.

Authors:  W W Sheng; S Soukup; K Bove; B Gotwals; B Lampkin
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

8.  Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors.

Authors:  J M McDonald; E C Douglass; R Fisher; C F Geiser; C E Krill; L C Strong; D Virshup; V Huff
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

9.  [Cytogenetic findings in Wilms' tumor].

Authors:  K Hohenfellner; M Holl; P Gutjahr; B Zabel
Journal:  Klin Padiatr       Date:  1989 Jul-Aug       Impact factor: 1.349

10.  The relationship between nephroblastoma and neurofibromatosis (Von Recklinghausen's disease).

Authors:  E J Stay; G Vawter
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.